Medreleaf Corp. (fka MEDFF)

[NYOptionsGuy]

MedReleaf to Sponsor Cancer Trial with Ontario Clinical Oncology
Group

MARKHAM, ON, July 12, 2018 -- /D.M.O. Newswire/ -- MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), in collaboration with the Ontario Clinical Oncology Group ("OCOG") today announced it will sponsor a cancer trial to improve the management of cancer pain using medical grade cannabis oil.



The OCOG directed by Dr. Mark Levine will coordinate the trial. Dr. Marissa Slaven, a specialist in pain management and palliative care is the Principal Investigator. The study will be conducted at the HHS Juravinski Cancer Centre in Hamilton over a one-two year period. Patients with cancer related pain will be administered MedReleaf's uniquely formatted cannabis oil capsules with the objective of improving pain management.



Cancer patients experiencing pain despite other pain medications may be eligible to participate. The aim of the trial is to assess the effect of cannabis oil in relieving their symptoms and to gain information on the best oral dosing regimen. Patients will receive an oil combining THC and CBD.


FULL RELEASE: https://www.dailymarijuanaobserver.com/single-post/2018/07/12/LEAF-MEDFF-MedReleaf-to-Sponsor-Cancer-Trial-with-Ontario-Clinical-Oncology-Group